Group 1 - The core viewpoint of the article is that Yipinhong has received clinical trial approval for its small molecule AM-001 from both the China National Medical Products Administration (CDE) and the U.S. Food and Drug Administration (FDA) [2] - The product AM-001 is a MRGPRX2 receptor modulator intended for the treatment of autoimmune diseases such as atopic dermatitis and urticaria [2] - The drug development process is characterized by long cycles, high investment, and significant risks, prompting the company to advise investors to make cautious decisions [2]

证券日报网讯12月29日，一品红（300723）发布公告称，公司将于2026年1月14日召开2026年第一次临 时股东会。 ...

每经AI快讯，一品红（SZ 300723，收盘价：34.51元）12月29日晚间发布公告称，公司第四届第十六次 董事会会议于2025年12月29日以现场结合通讯表决的方式召开。会议审议了《关于召开2026年第一次临 时股东会的议案》等文件。 2024年1至12月份，一品红的营业收入构成为：医药制造占比96.78%，医药代理占比3.22%。 截至发稿，一品红市值为156亿元。 每经头条（nbdtoutiao）——直击茅台经销商大会：2000多人周末齐聚！重大变革公布：涉及茅台酒价 格、分销等，董事长陈华：经销商不能再"躺着赚钱" （记者 曾健辉） ...

关于 2026 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、是否需要提交股东会审议：是 2、本次关联交易属公司日常关联交易，是以正常生产经营业务为基础，以 市场价格为定价依据，遵循公允、合理的原则，公司主营业务不会因上述交易对 关联方形成依赖，不会影响公司独立性，不存在损害公司及全体股东特别是中小 股东利益的行为。 一、日常关联交易基本情况 （一）日常关联交易概述及审批程序 根据一品红药业集团股份有限公司（以下简称"公司"）及子公司的日常经 营需要，公司及子公司预计 2026 年度将与关联方发生日常关联交易总金额累计 不超过 10,435.00 万元。 公司于 2025 年 12 月 29 日召开第四届董事会第十六次会议，审议通过了《关 于 2026 年度日常关联交易预计的议案》，关联董事李捍雄先生、李捍东先生回 避表决。出席会议的非关联董事一致表决通过该议案，并同意提交该议案至公司 临时股东会审议。该议案已经公司独立董事专门会议审议通过。 证券代码：300723 证券简称：一品红 公告编号：2025-097 ...

证券代码：300723 证券简称：一品红 公告编号：2025-098 一品红药业集团股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要提示： 一品红药业集团股份有限公司（以下简称"公司"）第四届董事会第十六次会议审议 通过，决定于 2026 年 1 月 14 日召开 2026 年第一次临时股东会。现将本次会议的相关事 项通知如下： 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》 等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2026 年 01 月 14 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 01 月 14 日 9:15-9:25，9:30-11:30，13:00-15:00； ...

证券代码：300723 证券简称：一品红 公告编号：2025-096 2026 年度，公司及子公司因日常经营需要，与关联方广州润尔眼科生物科 技有限公司（以下简称"润尔眼科"）及其子公司拟签署《一品红与润尔眼科 2026 年日常关联交易框架协议》（以下简称"框架协议"），预计发生关联交易不超过 3,500 万元;预计与关联方广州云润生物科技有限公司和吴美容女士租赁房产，及 与关联方重庆瑞泊莱医药科技有限公司和其子公司重庆瑞泊莱制药有限公司预 计发生关联交易不超过 6,935 万元。 一品红药业集团股份有限公司 第四届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 一品红药业集团股份有限公司（以下简称"公司"）第四届董事会第十六次 会议于 2025 年 12 月 29 日 14:30 以现场结合通讯表决的方式召开。本次会议通 知已于 2025 年 12 月 26 日以电话或电子邮件等方式向全体董事发出。会议由董 事长李捍雄先生主持，会议应到董事 5 人，实到董事 5 人。公司高管列席会议。 本次会议的召集、召开 ...

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 108.85%, but a recent decline over the past 20 and 60 days, indicating potential concerns about future performance [1][2]. Financial Performance - For the period from January to September 2025, Yipinhong reported a revenue of 814 million yuan, a year-on-year decrease of 34.35%, while the net profit attributable to shareholders was -136 million yuan, an increase of 44.80% compared to the previous year [2]. - The company has distributed a total of 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the last three years [3]. Stock Market Activity - As of December 25, Yipinhong's stock price was 35.63 yuan per share, with a trading volume of 150 million yuan and a market capitalization of 16.094 billion yuan [1]. - The stock has experienced a net outflow of 2.2549 million yuan from major funds, with significant buying and selling activity noted in large orders [1]. Shareholder Information - As of November 30, Yipinhong had 20,400 shareholders, a decrease of 1.73% from the previous period, with an average of 20,511 circulating shares per shareholder, an increase of 1.76% [2]. - New institutional shareholders include Hong Kong Central Clearing Limited and several mutual funds, indicating a shift in the shareholder base [3]. Business Overview - Yipinhong is primarily engaged in the research, production, and sales of its own pharmaceuticals, with a revenue composition of 61.12% from pediatric drugs, 22.71% from chronic disease medications, and 16.17% from other products [1]. - The company operates within the pharmaceutical and biotechnology sector, focusing on chemical pharmaceuticals and various therapeutic areas including hypertension and hepatitis [2].

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for the sodium valproate injection concentrated solution, which is classified as a Category B product under the national medical insurance scheme [1][2]. Group 1 - The sodium valproate injection concentrated solution is registered as a Class 3 chemical drug, which is considered to have passed the consistency evaluation [1][2]. - The approval of this product enhances the company's portfolio in the pharmaceutical market, particularly in the area of medications covered by national insurance [1][2]. - The announcement regarding the registration certificate was made public through an official notice by the company [2][3].

Core Viewpoint - The company Yipinhong (300723.SZ) has received a drug registration certificate for sodium valproate injection solution from the National Medical Products Administration, enabling it to sell this product in the domestic market [1] Group 1 - The approval of the sodium valproate injection solution registration certificate enhances the company's product pipeline and variety [1] - This development strengthens the company's competitiveness in the chronic disease medication sector [1]

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of sodium valproate injection solution, indicating a significant development in its product offerings [1] Group 1: Product Approval - Yipinhong's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for sodium valproate injection solution [1] - The approved indication for sodium valproate injection is for the treatment of epilepsy, particularly when oral formulations cannot be administered in adults and children [1] Group 2: Mechanism of Action - Sodium valproate exists in the blood as valproate ions, and its therapeutic mechanism is not fully understood [1] - The antiepileptic activity of sodium valproate may be related to the increase in the concentration of gamma-aminobutyric acid (GABA) in the brain [1]